nach oben

Erschienen in:

28.10.2023 | Chronic Pain Medicine (O Viswanath, Section Editor)

Buprenorphine for Chronic Pain Management: a Narrative Review

verfasst von: Peter D. Vu, Vishal Bansal, Ahish Chitneni, Christopher L. Robinson, Omar Viswanath, Ivan Urits, Alan D. Kaye, Anvinh Nguyen, Ranganathan Govindaraj, Grant H. Chen, Jamal Hasoon

Erschienen in: Current Pain and Headache Reports | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this review is to educate healthcare professionals regarding buprenorphine for the use of opioid use disorder (OUD) as well as for chronic pain management. This review provides physicians and practitioners with updated information regarding the distinct characteristics and intricacies of prescribing buprenorphine.

Recent Findings

Buprenorphine is approved by the US Food and Drug Administration (FDA) for acute pain, chronic pain, opioid use disorder (OUD), and opioid dependence. When compared to most other opioids, buprenorphine offers superior patient tolerability, an excellent half-life, and minimal respiratory depression. Buprenorphine does have notable side effects as well as pharmacokinetic properties that require special attention, especially if patients require future surgical interventions.

Summary

Many physicians are not trained to initiate or manage patients on buprenorphine. However, buprenorphine offers a potentially safer alternative for medication management for patients who require chronic opioid therapy for pain or have OUD. This review provides updated information on buprenorphine for both chronic pain and OUD.

Dahlhamer J, Lucas J, Zelaya, Carla, et al. Prevalence of chronic pain and high-impact chronic pain among adults — United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–1006. https://doi.org/10.15585/mmwr.mm6736a2.

Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. U.S. Department of Health and Human Services.

Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16. https://doi.org/10.1037/a0013628.CrossRefPubMedPubMedCentral

Dalal S, Chitneni A, Berger AA, et al. Buprenorphine for chronic pain: a safer alternative to traditional opioids. Health Psychol Res. 2021;9(1). https://doi.org/10.52965/001c.27241.

Poliwoda S, Noor N, Jenkins JS, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3). https://doi.org/10.52965/001c.37517.

Gress K, Charipova K, Jung JW, et al. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):449–61. https://doi.org/10.1016/j.bpa.2020.06.003.CrossRefPubMed

Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol. United States Department of Health and Human Services.

Windish DM, Catalanotti JS, Zaas A, Kisielewski M, Moriarty JP. Training in safe opioid prescribing and treatment of opioid use disorder in internal medicine residencies: a National Survey of Program Directors. J Gen Intern Med. 2022;37(11):2650–60. https://doi.org/10.1007/s11606-021-07102-y.CrossRefPubMed

Hasoon J, Nguyen A, Urits I, Robinson C, Viswanath O, Kaye AD. A need for further education on buprenorphine in pain medicine. Health Psychol Res. 2023;11. https://doi.org/10.52965/001c.74958.

10.

Speight C, Caiola C, Tyndall DE, Scott ES. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings. J Am Assoc Nurse Pract. 2023;35(2):112–21. https://doi.org/10.1097/JXX.0000000000000811.CrossRefPubMed

11.

McAllister W. Drug Diplomacy in the Twentieth Century. 1999;1.

12.

Acker C. Creating the American Junkie. 2006;1.

13.

Jasinski DR. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry. 1978;35(4):501. https://doi.org/10.1001/archpsyc.1978.01770280111012.CrossRefPubMed

14.

Lewis JW. Buprenorphine. Drug Alcohol Depend. 1985;14(3–4):363–72. https://doi.org/10.1016/0376-8716(85)90067-5.CrossRefPubMed

15.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43(1):72–8. https://doi.org/10.1038/clpt.1988.13.CrossRefPubMed

16.

Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750–5.CrossRefPubMed

17.

Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence. JAMA. 2010;304(14):1576. https://doi.org/10.1001/jama.2010.1427.CrossRefPubMed

18.

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–58. https://doi.org/10.1056/NEJMoa022164.CrossRefPubMed

19.

Bliley T. Drug Addiction Treatment Act of 2000 . https://www.congress.gov/bill/106th-congress/house-bill/2634.

20.

FDA Approves First Generic Versions of Suboxone Sublingual Film, Which May Increase Access to Treatment for Opioid Dependence. United States Food and Drug Administration; 2018.

21.

White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine)^® for treatment of heroin dependence. Drug Alcohol Depend. 2009;103(1–2):37–43. https://doi.org/10.1016/j.drugalcdep.2009.03.008.CrossRefPubMed

22.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine. JAMA. 2016;316(3):282. https://doi.org/10.1001/jama.2016.9382.CrossRefPubMed

23.

FDA Approves First Buprenorphine Implant for Treatment of Opioid Dependence. United States Food and Drug Administration; 2016.

24.

Laffont CM, Gomeni R, Heidbreder C, Jones JP, Nasser AF. Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder. J Clin Pharmacol. 2016;56(7):806–15. https://doi.org/10.1002/jcph.665.CrossRefPubMed

25.

Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2019;393(10173):778–90. https://doi.org/10.1016/S0140-6736(18)32259-1.CrossRef

26.

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder. 2018.

27.

Andorn AC, Haight BR, Shinde S, et al. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis. J Clin Psychopharmacol. 2020;40(3):231–9. https://doi.org/10.1097/JCP.0000000000001195.CrossRefPubMedPubMedCentral

28.

FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. United States Food and Drug Administration. 2017.

29.

Saltmer C. FDA Accepts Braeburn’s new drug application resubmission for BRIXADI^TM (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder. Braeburn. December 8, 2022.

30.

Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(08):e785–93. https://doi.org/10.4088/JCP.13m08725.CrossRefPubMedPubMedCentral

31.

Khroyan TV, Wu J, Polgar WE, et al. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol. 2015;172(2):668–80. https://doi.org/10.1111/bph.12796.CrossRefPubMed

32.

Kranzler HR, Lynch KG, Crist RC, et al. A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder. Int J Neuropsychopharmacol. 2021;24(2):89–96. https://doi.org/10.1093/ijnp/pyaa069.CrossRefPubMed

33.

Zhuo GY, Chen MC, Lin TY, Lin ST, Chen DTL, Lee CWS. Opioid-modulated receptor localization and Erk1/2 phosphorylation in cells coexpressing μ-opioid and nociceptin receptors. Int J Mol Sci. 2023;24(2):1048. https://doi.org/10.3390/ijms24021048.CrossRefPubMedPubMedCentral

34.

De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425–36. https://doi.org/10.1007/s40261-021-01032-7.CrossRefPubMedPubMedCentral

35.

Khanna I, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. Published online December 2015:859. https://doi.org/10.2147/JPR.S85951.

36.

Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine Palliat Med. 2006;20(Suppl 1):s17-23.CrossRefPubMed

37.

Soyka M, Backmund M, Schmidt P, Apelt S. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. Am J Addict. 2014;23(6):563–9. https://doi.org/10.1111/j.1521-0391.2014.12131.x.CrossRefPubMed

38.

Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–32. https://doi.org/10.1093/bja/ael051.CrossRefPubMed

39.

Spreen LA, Dittmar EN, Quirk KC, Smith MA. Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review. Pharmacotherapy J Human Pharmacol Drug Ther. 2022;42(5):411–427. https://doi.org/10.1002/phar.2676.

40.

DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–17. https://doi.org/10.1124/jpet.112.201616.CrossRefPubMed

41.

Mores KL, Cassell RJ, van Rijn RM. Arrestin recruitment and signaling by G protein-coupled receptor heteromers. Neuropharmacology. 2019;152:15–21. https://doi.org/10.1016/j.neuropharm.2018.11.010.CrossRefPubMed

42.

Mori T, Kuzumaki N, Arima T, et al. Usefulness for the combination of G protein- and β-arrestin-biased ligands of μ-opioid receptors: prevention of antinociceptive tolerance. Mol Pain. 2017;13:174480691774003. https://doi.org/10.1177/1744806917740030.CrossRef

43.

Pedersen MF, Wróbel TM, Märcher-Rørsted E, et al. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. Neuropharmacology. 2020;166: 107718. https://doi.org/10.1016/j.neuropharm.2019.107718.CrossRefPubMed

44.

Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Buprenorphine: far beyond the “ceiling.” Biomolecules. 2021;11(6):816. https://doi.org/10.3390/biom11060816.CrossRefPubMedPubMedCentral

45.

Navratilova E, Ji G, Phelps C, et al. Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. Pain. 2019;160(4):824–32. https://doi.org/10.1097/j.pain.0000000000001458.CrossRefPubMedPubMedCentral

46.

Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93–103. https://doi.org/10.1097/ADM.0000000000000457.CrossRefPubMedPubMedCentral

47.

Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19. https://doi.org/10.1016/j.suponc.2012.05.002.CrossRefPubMed

48.

Pergolizzi JV, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015;53(2):71–6. https://doi.org/10.1016/j.aat.2015.06.001.CrossRefPubMed

49.

Hakomäki H, Eskola S, Kokki H, et al. Central nervous system distribution of buprenorphine in pregnant sheep, fetuses and newborn lambs after continuous transdermal and single subcutaneous extended-release dosing. Eur J Pharm Sci. 2022;178: 106283. https://doi.org/10.1016/j.ejps.2022.106283.CrossRefPubMed

50.

Mestre H, Mori Y, Nedergaard M. The brain’s glymphatic system: current controversies. Trends Neurosci. 2020;43(7):458–66. https://doi.org/10.1016/j.tins.2020.04.003.CrossRefPubMedPubMedCentral

51.

Lilius TO, Blomqvist K, Hauglund NL, et al. Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs. J Control Release. 2019;304:29–38. https://doi.org/10.1016/j.jconrel.2019.05.005.CrossRefPubMed

52.

Pergolizzi JV, Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;12:3299–317. https://doi.org/10.2147/JPR.S231948.CrossRefPubMed

53.

Bohme K. Buprenorphine in a transdermal therapeutic system – a new option. Clin Rheumatol. 2002;21(S1):S13–6. https://doi.org/10.1007/s100670200031.CrossRefPubMed

54.

Gianni W, Madaio AR, Ceci M, et al. Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old. J Pain Symptom Manage. 2011;41(4):707–14. https://doi.org/10.1016/j.jpainsymman.2010.06.015.CrossRefPubMed

55.

Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, phase iii, randomized, open-label, crossover comparison. Clin Ther. 2007;29(8):1591–606. https://doi.org/10.1016/j.clinthera.2007.08.001.CrossRefPubMed

56.

Yarlas A, Miller K, Wen W, et al. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. Postgrad Med. 2015;127(1):38–45. https://doi.org/10.1080/00325481.2014.992715.CrossRefPubMed

57.

Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Pain. 2016;157(11):2517–26. https://doi.org/10.1097/j.pain.0000000000000670.CrossRefPubMedPubMedCentral

58.

Hale M, Urdaneta V, Kirby T, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–40. https://doi.org/10.2147/JPR.S120170.CrossRefPubMedPubMedCentral

59.

Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009;31(3):503–13. https://doi.org/10.1016/j.clinthera.2009.03.001.CrossRefPubMed

60.

Pace MC. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci. 2007;12(1):1291. https://doi.org/10.2741/2147.CrossRefPubMed

61.

Leng X, Li Z, Lv H, et al. Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain. Clin J Pain. 2015;31(7):612–20. https://doi.org/10.1097/AJP.0000000000000144.CrossRefPubMed

62.

Raffa RB, Haidery M, Huang HM, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014;39(6):577–83. https://doi.org/10.1111/jcpt.12196.CrossRefPubMed

63.

Jonan AB, Kaye AD, Urman RD. Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures. Pain Physician. 2018;21(1):E1–12.PubMed

64.

Hale M, Garofoli M, Raffa RB. Benefit-risk analysis of buprenorphine for pain management. J Pain Res. 2021;14:1359–69. https://doi.org/10.2147/JPR.S305146.CrossRefPubMedPubMedCentral

65.

Mercieri M, Palmisani S, De Blasi RA, et al. Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial. Br J Anaesth. 2017;119(4):792–802. https://doi.org/10.1093/bja/aex174.CrossRefPubMed

66.

Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med. 2014;15(7):1171–8. https://doi.org/10.1111/pme.12386.CrossRefPubMed

67.

Boom M, Niesters M, Sarton E, Aarts LW, Smith T, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994–6004. https://doi.org/10.2174/138161212803582469.

68.

Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20(Suppl 1):s3-8.CrossRefPubMed

69.

Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006;10(8):743–743. https://doi.org/10.1016/j.ejpain.2005.12.001.CrossRefPubMed

70.

Plosker GL. Buprenorphine 5, 10 and 20 μg/h Transdermal Patch. Drugs. 2011;71(18):2491–509. https://doi.org/10.2165/11208250-000000000-00000.CrossRefPubMed

71.

• Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211–28. https://doi.org/10.1007/s40265-018-0953-z. This review discusses buprenorphine use in certain populations and provides a synopsis of systematic reviews and randomized analgesic trials.CrossRefPubMedPubMedCentral

72.

Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–53.CrossRefPubMed

73.

Cuer JC, Dapoigny M, Ajmi S, et al. Effects of buprenorphine on motor activity of the sphincter of Oddi in man. Eur J Clin Pharmacol. 1989;36(2):203–4. https://doi.org/10.1007/BF00609196.CrossRefPubMed

74.

Kumar R, Viswanath O, Saadabadi A. Buprenorphine. StatPearls. 2023.

75.

Shmygalev S, Damm M, Weckbecker K, Berghaus G, Petzke F, Sabatowski R. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug Alcohol Depend. 2011;117(2–3):190–7. https://doi.org/10.1016/j.drugalcdep.2011.01.017.CrossRefPubMed

76.

Sittl R, Nuijten M, Poulsen NB. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther. 2006;28(8):1144–54. https://doi.org/10.1016/j.clinthera.2006.08.002.CrossRefPubMed

77.

Strain E, Peavy M. Approach to treating opioid use disorder. UpToDate.

78.

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–67. https://doi.org/10.1097/ADM.0000000000000166.CrossRefPubMedPubMedCentral

79.

Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628. https://doi.org/10.7326/M18-1652.CrossRefPubMed

80.

Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To stop or not, that is the question. Anesthesiology. 2017;126(6):1180–6. https://doi.org/10.1097/ALN.0000000000001633.CrossRefPubMed

81.

Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. (SMA) 04–3939. Substance Abuse and Mental Health Services Administration. 2004.

82.

Kornfeld H, Manfredi L. Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: a case series. Am J Ther. 2010;17(5):523–8. https://doi.org/10.1097/MJT.0b013e3181be0804.CrossRefPubMed

83.

Macintyre PE, Russell RA, Usher KAN, Gaughwin M, Huxtable CA. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013;41(2):222–30. https://doi.org/10.1177/0310057X1304100212.CrossRefPubMed

84.

• Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840–59. https://doi.org/10.1136/rapm-2021-103007. This paper provides an overview of buprenorphine, including pharmacology and legal statutes along with providing multisociety consensus recommendations.CrossRefPubMed

85.

Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12(3):679–84.CrossRefPubMed

86.

Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage. 2006;32(2):175–9. https://doi.org/10.1016/j.jpainsymman.2006.01.013.CrossRefPubMed

87.

Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57. https://doi.org/10.1016/j.jsat.2014.12.011.CrossRefPubMed

88.

Mendoza S, Rivera-Cabrero AS, Hansen H. Shifting blame: buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry. 2016;53(4):465–87. https://doi.org/10.1177/1363461516660884.CrossRefPubMedPubMedCentral

89.

Mancher M, Leshner AI. Medications for Opioid Use Disorder Save Lives. (Leshner AI, Mancher M, eds.). National Academies Press; 2019. https://doi.org/10.17226/25310.

90.

Madras BK, Ahmad NJ, Wen J, Sharfstein J. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspectives. Published online April 27, 2020. https://doi.org/10.31478/202004b.

91.

Sharfstein JM, Olsen Y. Making amends for the opioid epidemic. JAMA. 2019;321(15):1446–7. https://doi.org/10.1001/jama.2019.3505.CrossRefPubMed

92.

Waiver Elimination (MAT Act). 2022. https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act.

93.

Elimination of X-waiver removes major barrier to opioid use disorder treatment. American College of Physicians.

94.

Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–25. https://doi.org/10.1080/10550887.2012.694598.CrossRefPubMedPubMedCentral

95.

• American Society of Addiction Medicine. ASAM National Practice Guideline for the Treatment of Opioid Use Disorder – 2020 Focused Update.; 2020. This is the national practice guidelines for the treatment of OUD.

96.

Huskamp HA, Riedel LE, Barry CL, Busch AB. Coverage of medications that treat opioid use disorder and opioids for pain management in marketplace plans, 2017. Med Care. 2018;56(6):505–9. https://doi.org/10.1097/MLR.0000000000000918.CrossRefPubMedPubMedCentral

97.

Fishman MA, Kim PS. Buprenorphine for chronic pain: a systemic review. Curr Pain Headache Rep. 2018;22(12):83. https://doi.org/10.1007/s11916-018-0732-2.CrossRefPubMed

98.

Aiyer R, Gulati A, Gungor S, Bhatia A, Mehta N. Treatment of chronic pain with various buprenorphine formulations. Anesth Analg. 2018;127(2):529–38. https://doi.org/10.1213/ANE.0000000000002718.CrossRefPubMed

99.

Erosa SC, Haffey PR, Mehta N, Gulati A. Tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain: a systematic review. Curr Pain Headache Rep. 2021;25(3):18. https://doi.org/10.1007/s11916-020-00934-z.CrossRefPubMed

100.

Lazaridou A, Paschali M, Edwards RR, Gilligan C. Is Buprenorphine effective for chronic pain? A systematic review and meta-analysis. Pain Med. 2020;21(12):3691–9. https://doi.org/10.1093/pm/pnaa089.CrossRefPubMed

101.

Wong SSC, Chan TH, Wang F, Chan TCW, Ho HC, Cheung CW. Analgesic effect of buprenorphine for chronic noncancer pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg. Published online March 24, 2023. https://doi.org/10.1213/ANE.0000000000006467.

Titel: Buprenorphine for Chronic Pain Management: a Narrative Review
verfasst von: Peter D. Vu
Vishal Bansal
Ahish Chitneni
Christopher L. Robinson
Omar Viswanath
Ivan Urits
Alan D. Kaye
Anvinh Nguyen
Ranganathan Govindaraj
Grant H. Chen
Jamal Hasoon
Publikationsdatum: 28.10.2023
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports / Ausgabe 12/2023
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-023-01185-4

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Buprenorphine for Chronic Pain Management: a Narrative Review

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

Reanimation bei Kindern – besser vor Ort oder während Transport?

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Update AINS

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

Reanimation bei Kindern – besser vor Ort oder während Transport?

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Update AINS